Coherus Oncology, Inc. (CHRS)

Current Report Filed: 2026-05-11

Key Insights

Coherus Oncology released Q1 2026 financial results on May 11, 2026, indicating the company is actively reporting operational performance to shareholders and the market.
The 8-K filing is limited to earnings disclosure with no mention of material agreements, leadership changes, acquisitions, or other significant corporate events that would typically warrant separate disclosure.
As a non-emerging growth company, Coherus Oncology is subject to full SEC compliance requirements and SOX 404 auditing standards, indicating it has matured from its earlier stage.
The press release (Exhibit 99.1) containing detailed financial results is not incorporated by reference, limiting legal liability but requiring investors to access the full release separately for complete earnings context.

Quarterly Report Filed: 2026-05-11

Key Insights

Company executed a public offering in February 2026 and raised capital through a sales agreement, indicating active capital management and potential liquidity needs or strategic investment opportunities.
Portfolio includes discontinued operations (Udeneya, Loqtorzi, Cimerly) suggesting portfolio rationalization and focus shift toward core oncology assets, particularly Toripalimab.
Significant debt obligations include convertible senior subordinated notes due 2026 and 2029 term loans, creating near-term refinancing risk and potential dilution to shareholders.
Revenue concentration risk exists with three major pharmaceutical distributors (McKesson, Cencora, Cardinal) representing substantial portions of sales, creating customer dependency vulnerability.
Company maintains investment portfolio including treasury securities and corporate notes, demonstrating liquidity management but also suggesting ongoing cash burn requiring working capital preservation.

Current Report Filed: 2026-03-09

Key Insights

Coherus Oncology, Inc. reported its Q4 2025 and full-year 2025 financial results, providing investors with an update on the company's performance.
The company's press release indicates that it experienced growth in both quarterly and annual revenue, suggesting positive momentum in its business.
However, the filing does not provide detailed financial figures or guidance for the upcoming year, limiting the ability to fully assess the company's financial health and future prospects.

Annual Report Filed: 2026-03-09

Key Insights

Coherus Oncology, Inc. reported a significant increase in research and development expenses in 2025, suggesting a focus on advancing their oncology pipeline.
The company recorded a non-operating gain from the sale of its Yusimry Immunology Franchise, which may provide financial flexibility to support ongoing operations.
Coherus Oncology's revenue from the Toripalimab product declined in 2025 compared to the previous year, which could indicate increasing competitive pressures in the market.

Current Report Filed: 2026-02-17

Key Insights

Coherus Oncology, Inc. (CHRS) completed a public offering of 28.6 million shares of common stock, raising approximately $47 million in net proceeds.
The company granted the underwriters an option to purchase up to an additional 4.29 million shares to cover any over-allotments.
Coherus Oncology, its directors, executive officers, and certain affiliated stockholders have agreed to a 60-day lock-up period on selling or transferring shares, subject to certain exceptions.

Current Report Filed: 2026-02-04

Key Insights

Coherus Oncology, Inc. has entered into a clinical supply agreement with Janssen to evaluate their investigational anti-CCR8 cytolytic monoclonal antibody, tagmokitug, in combination with Janssen's T-cell engaging bispecific antibody, pasritamig, in a Phase 1b clinical study for metastatic castration-resistant prostate cancer (mCRPC).
Under the terms of the agreement, Janssen will provide pasritamig to Coherus, who will be the sponsor of the Phase 1b trial, while both companies retain commercial rights to their respective compounds.
This collaboration could potentially lead to the development of a novel combination therapy for mCRPC, which is an important area of unmet medical need.

Insider Trading Filed: 2026-01-26

Key Insights

Coherus Oncology's Chief Financial Officer, Bryan J. McMichael, has acquired 112,500 restricted stock units (RSUs) and 225,000 stock options, indicating potential confidence in the company's future performance.
The RSUs vest 50% in May 2027 and 50% in March 2029, while the stock options vest over 4 years, suggesting a long-term commitment from the executive.
The substantial equity grants, both in RSUs and stock options, may align the CFO's interests with those of shareholders and signal the company's focus on long-term growth.

Insider Trading Filed: 2026-01-26

Key Insights

The reporting person, Dennis M. Lanfear, was granted 375,000 restricted stock units (RSUs) on January 23, 2026, which will vest over time as he continues his service as the President and CEO of Coherus Oncology, Inc.
Lanfear also holds 432,684 shares of Coherus Oncology's common stock through a trust and 86,965 shares through an LLC, indicating his significant equity ownership in the company.
Lanfear was granted a stock option to purchase 750,000 shares of Coherus Oncology's common stock, which will vest over time as he continues his service with the company.

Current Report Filed: 2026-01-23

Key Insights

Coherus Oncology has filed a prospectus supplement to sell up to $64.88 million worth of common stock through a sales agreement with TD Cowen, providing additional funding for the company.
The company has made several amendments to the sales agreement since it was initially established in 2022, indicating ongoing flexibility and adaptability in its capital raising strategy.
The legal opinion from Latham & Watkins LLP regarding the validity of the stock issuance suggests that the company is taking the necessary steps to ensure compliance and transparency for investors.

Insider Trading Filed: 2026-01-22

Key Insights

The filing indicates that Dennis M. Lanfear, the President and CEO of Coherus Oncology, Inc., has disposed of 11,839 shares of the company's common stock. This appears to be a routine transaction to cover tax liabilities associated with the vesting of restricted stock units.
Lanfear also holds a significant indirect beneficial ownership in the company, with 432,684 shares held through the Lanfear Revocable Trust and 86,965 shares held through Lanfear Capital Advisors, LLC. This suggests a substantial alignment of his interests with those of the company's shareholders.
The filing does not indicate any significant changes in Lanfear's overall ownership position, suggesting a relatively stable leadership and ownership structure at Coherus Oncology.

Insider Trading Filed: 2026-01-22

Key Insights

The reporting person, Bryan J. McMichael, the Chief Financial Officer of Coherus Oncology, Inc., has disposed of 1,715 shares of common stock through an automatic withholding transaction to pay related tax liability, indicating he continues to hold a significant position in the company.
The transaction occurred on January 20, 2026, suggesting ongoing insider activity and engagement with the company's equity compensation program.
The reported transaction price of $1.55 per share may provide insight into the current market valuation of Coherus Oncology's stock.

Current Report Filed: 2026-01-13

Key Insights

Coherus Oncology provided preliminary unaudited financial results for Q4 2025 and FY 2025, including net revenues and cash/investments as of December 31, 2025.
The company's preliminary financial results are not final and may change significantly based on the completion of the full financial closing procedures.
Coherus Oncology cautioned that the preliminary results have not been reviewed or audited by its independent registered public accounting firm.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information